Clinical Trial Suggests Special Toothpaste May Suppress Peanut Allergies in Adults

Phase 1 Trial of Peanut-Allergy Suppressing Toothpaste Shows Promising Safety Data; FDA Greenlights Trials for Children Aged 4-17

The toothpaste, named INT301, is designed to suppress peanut allergies in adults by gradually introducing them to small, controlled amounts of the allergen, according to a Phase 1 clinical trial.
INT301 employs oral mucosal immunotherapy (OMIT), using the immune response cells in the lining of the mouth to desensitize patients to their allergens.
During the trial, participants brushed their teeth with the toothpaste once daily for approximately 11 months, and no participants reported severe reactions or anaphylaxis.
Following the successful adult trials, the U.S. Food and Drug Administration has approved Phase 1 clinical trials for children aged 4 to 17.
The toothpaste could offer a safer and more convenient alternative to current treatments for peanut allergies such as injections, and could potentially be expanded to other common food allergens.